Published in Cancer Res on December 15, 2003
Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 2.21
Heparanase: busy at the cell surface. Trends Biochem Sci (2009) 2.07
Mammalian heparanase: what is the message? J Cell Mol Med (2007) 1.91
Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J (2010) 1.78
Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem (2008) 1.74
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood (2007) 1.65
Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood (2010) 1.61
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood (2007) 1.49
Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem (2013) 1.49
Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One (2009) 1.46
Significance of heparanase in cancer and inflammation. Cancer Microenviron (2011) 1.46
Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb (2009) 1.41
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40
Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res (2008) 1.35
The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia (2009) 1.33
Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest (2011) 1.32
Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer (2008) 1.31
Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes (2011) 1.29
Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia (2006) 1.28
Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis (2007) 1.27
Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Res (2010) 1.18
Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem (2010) 1.16
Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem (2011) 1.15
Heparanase activates the syndecan-syntenin-ALIX exosome pathway. Cell Res (2015) 1.14
Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res (2008) 1.13
A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J (2009) 1.13
An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun (2006) 1.03
Interstitial fluid: the overlooked component of the tumor microenvironment? Fibrogenesis Tissue Repair (2010) 1.02
Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res (2011) 1.00
Heparanase cooperates with Ras to drive breast and skin tumorigenesis. Cancer Res (2014) 0.99
Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival. Neoplasia (2006) 0.98
Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol (2012) 0.98
Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J Cell Biochem (2009) 0.98
Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget (2016) 0.96
Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. J Biol Chem (2012) 0.94
Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion. Neoplasia (2005) 0.93
Impact of heparanase and the tumor microenvironment on cancer metastasis and angiogenesis: basic aspects and clinical applications. Rambam Maimonides Med J (2011) 0.92
Heparanase is a host enzyme required for herpes simplex virus-1 release from cells. Nat Commun (2015) 0.92
Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme. J Natl Cancer Inst (2014) 0.89
Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Rev Mol Diagn (2010) 0.87
Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis. Proc Natl Acad Sci U S A (2016) 0.85
Fibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-Cell Interactions. J Biol Chem (2015) 0.85
Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis. J Bone Miner Res (2010) 0.84
Myeloma cell-derived Runx2 promotes myeloma progression in bone. Blood (2015) 0.83
Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease. Bone (2013) 0.83
Glucose Starvation in Cardiomyocytes Enhances Exosome Secretion and Promotes Angiogenesis in Endothelial Cells. PLoS One (2015) 0.82
Suppression of Wnt1-induced mammary tumor growth and lower serum insulin in offspring exposed to maternal blueberry diet suggest early dietary influence on developmental programming. Carcinogenesis (2012) 0.82
Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis (2016) 0.81
Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma. J Cell Mol Med (2013) 0.81
The mechanisms and physiological relevance of glycocalyx degradation in hepatic ischemia/reperfusion injury. Antioxid Redox Signal (2014) 0.81
Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J (2016) 0.80
Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity. Oncogene (2015) 0.79
Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. Matrix Biol (2016) 0.79
Heparanase is preferentially expressed in human psoriatic lesions and induces development of psoriasiform skin inflammation in mice. Cell Mol Life Sci (2013) 0.78
Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells. Oncotarget (2016) 0.77
Heparanase and coagulation-new insights. Rambam Maimonides Med J (2014) 0.77
Myeloma bone disease. J Bone Miner Res (2009) 0.77
Heparanase-A Link between Coagulation, Angiogenesis, and Cancer. Rambam Maimonides Med J (2012) 0.77
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. J Leukoc Biol (2017) 0.77
Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma. Am J Pathol (2016) 0.75
Tumor Microenvironment Modulation via Gold Nanoparticles Targeting Malicious Exosomes: Implications for Cancer Diagnostics and Therapy. Int J Mol Sci (2017) 0.75
Effects of receptor for advanced glycation endproducts on microvessel formation in endometrial cancer. BMC Cancer (2016) 0.75
A simple assay to probe disease-associated enzyme activity using glycosaminoglycan-assisted synthesized gold nanoparticles. Org Biomol Chem (2008) 0.75
Mechanisms of heparanase inhibitors in cancer therapy. Exp Hematol (2016) 0.75
Increased expression of heparanase in osteogenic differentiation of rat marrow stromal cells. Exp Ther Med (2013) 0.75
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
The sequence and de novo assembly of the giant panda genome. Nature (2009) 15.76
Containing pandemic influenza with antiviral agents. Am J Epidemiol (2004) 12.82
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80
The molecular classification of multiple myeloma. Blood (2006) 8.77
Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med (2006) 7.89
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
Containing bioterrorist smallpox. Science (2002) 7.62
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation (2004) 4.79
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell (2005) 4.73
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
A polymer tandem solar cell with 10.6% power conversion efficiency. Nat Commun (2013) 4.48
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04
Do birth cohorts matter? Age-period-cohort analyses of the obesity epidemic in the United States. Soc Sci Med (2009) 3.87
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol (2006) 3.48
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol (2007) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate--a prospective, randomized, and controlled clinical trial. Radiology (2013) 3.32
Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 3.28
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood (2008) 3.22
Neuronal basis of age-related working memory decline. Nature (2011) 3.15
Multiple myeloma: clinical review and diagnostic imaging. Radiology (2004) 3.12
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res (2003) 3.09
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood (2009) 3.02
Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci U S A (2010) 2.94
High-throughput solution processing of large-scale graphene. Nat Nanotechnol (2008) 2.93
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 2.91
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol (2008) 2.82
Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med (2002) 2.81
Patterning organic single-crystal transistor arrays. Nature (2006) 2.80
Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine (2007) 2.76
The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci (2012) 2.71
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol (2008) 2.64
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
A practical comparison of de novo genome assembly software tools for next-generation sequencing technologies. PLoS One (2011) 2.55
VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem (2002) 2.53
Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation (2008) 2.53
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood (2002) 2.48
NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex. Neuron (2013) 2.46
Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity (2010) 2.44
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 2.40
Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain Behav Immun (2008) 2.37
Nav1.8 expression is not restricted to nociceptors in mouse peripheral nervous system. Pain (2012) 2.34
Engaging in an auditory task suppresses responses in auditory cortex. Nat Neurosci (2009) 2.34
Treatment of multiple myeloma. Blood (2003) 2.34
Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry (2011) 2.33
Murine B7-H3 is a negative regulator of T cells. J Immunol (2004) 2.33
Planar heterojunction perovskite solar cells via vapor-assisted solution process. J Am Chem Soc (2013) 2.32
Containing a large bioterrorist smallpox attack: a computer simulation approach. Int J Infect Dis (2006) 2.29
Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis (2008) 2.26
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer (2004) 2.26
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem (2007) 2.25
Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 2.21
Protein 4.1R-dependent multiprotein complex: new insights into the structural organization of the red blood cell membrane. Proc Natl Acad Sci U S A (2008) 2.18
Association of the beta2-adrenergic receptor gene with essential hypertension in the non-Han Chinese Yi minority human population. J Hypertens (2006) 2.16
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res (2008) 2.13
Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology (2011) 2.13
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol (2007) 2.13
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol (2009) 2.12
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica (2006) 2.11
Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis (2010) 2.10
Heparanase: busy at the cell surface. Trends Biochem Sci (2009) 2.07